Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    Advanced Search
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Canadian Federal Government
        • Canadian Municipal Government
        • Canadian Provincial Government
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Advanced Search
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • IR
    • All Products
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices
    • Hamburger menu
    • Cision Canada
    • Send a Release
    • FR
      • Phone

      • 877-269-7890 from 8 AM - 10 PM ET

      • ALL CONTACT INFO
      • Contact Cision

        877-269-7890
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • 3 News in Focus
      • 5 Business
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • IR
      • All Products
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media
      • Worldwide Offices
      • General Enquiries
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business) Business
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      CIPHER REPORTS Q3 2010 FINANCIAL RESULTS


      News provided by

      Cipher Pharmaceuticals Inc.

      Oct 27, 2010, 07:00 ET

      Share this article

      Share this article


      Toronto Stock Exchange Symbol: DND

      MISSISSAUGA, ON, Oct. 27 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and nine months ended September 30, 2010.

          
          Q3 2010 Summary
          ---------------
      
          -  Net revenue of $1.1 million for Q3 2010, consistent with Q3 2009, and
             $4.2 million for the 2010 fiscal year to date, an increase of 80% over
             the same nine-month period last year.
          -  Net loss for the third quarter was $0.3 million ($0.01 per share),
             compared with a loss of $0.5 million ($0.02 per share) for Q3 2009.
          -  Increased cash to $10.5 million at quarter end, compared with cash of
             $9.0 million at December 31, 2009.
          -  Announced that the U.S. Patent and Trademark Office issued a Patent
             Notice of Allowance for the Company's extended-release tramadol
             product, CIP-TRAMADOL ER.
          -  Subsequent to quarter end, also received Patent Notice of Allowance
             from the Canadian Intellectual Property Office.
          
      

      "We are pleased to see continued strength in Lipofen(R) prescriptions, which is providing a steadily increasing royalty stream that is substantially offsetting our operating expenses," said Larry Andrews, President and CEO of Cipher. "In the past several months, we achieved another important commercialization milestone as we received patent Notice of Allowances in the U.S. and Canada for our extended-release tramadol, providing important IP protection as we prepare to launch the product. In addition, we made excellent progress with our Phase III CIP-ISOTRETINOIN safety study during the quarter, and patient enrolment is expected to be completed this month - ahead of our original schedule. With more than 800 patients, this is the most comprehensive trial ever conducted on isotretinoin."

          
          Financial Review
          ----------------
          
      

      Net revenue in Q3 2010 was $1.1 million, the same as in Q3 2009. However, royalty revenue from Lipofen(R) product sales increased by $0.4 million year-over-year as revenue for Q3 2009 included a one-time $0.4 million payment from Cipher's marketing partner related to a minimum guarantee on Lipofen(R) sales.

      Gross Research and Development ("R&D") expenditures for Q3 2010 were $2.7 million, which represents an increase of $2.2 million compared with Q3 2009, driven by the CIP-ISOTRETINOIN clinical study. The reported R&D expenditure amount of $0.2 million for Q3 2010 is net of $2.5 million ($0.2 million in Q3 2009) of reimbursed expenses from Cipher's U.S. marketing partner. Operating, General and Administrative expense for Q3 2010 was $1.0 million, $0.2 million lower than the same period in the prior year.

      For the three months ended September 30, 2010, the Company recorded a net loss of $0.3 million ($0.01 per share), compared with a loss of $0.5 million ($0.02 per share) in Q3 2009.

      Net revenue for the first nine months of 2010 was $4.2 million, an increase of 80% over the $2.3 million recorded in first nine months of 2009. Net loss for the first nine months of 2010 was $0.03 million ($0.00 per share), compared with a net loss of $2.1 million ($0.09 per share) for the corresponding period last year.

      Cipher's financial position remained solid at quarter-end. As at September 30, 2010, the Company had cash of $10.5 million, compared with $9.0 million as at December 31, 2009 and $10.3 as at June 30, 2010.

          
          Product Update
          --------------
          
      

      During Q3 2010, Lipofen(R) monthly prescriptions in the U.S. market remained strong. Total monthly prescriptions for Q3 2010 rose 7% over Q2 2010.

      During Q3 2009, Cipher commenced its final Phase III safety trial for CIP-ISOTRETINOIN under a Special Protocol Assessment ("SPA") with the U.S. Food and Drug Administration ("FDA"). The 800-patient study is a double-blind, randomized trial comparing CIP-ISOTRETINOIN to an FDA-approved, commercially available isotretinoin product. The study is being conducted in the U.S. and Canada over an 18-month period. During Q3 2010, the Company completed patient screening, and enrolment is expected to be completed in October 2010. Following an approximate six-month treatment period and two months to compile and review the data, Cipher expects to disclose top-line study results in Q3 2011.

      In May 2010, Cipher announced that the FDA has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the treatment of moderate to moderately severe chronic pain in adults. Also during Q2 2010, the United States Court of Appeals upheld the lower court's original decision on patent infringement litigation initiated by Pharma Products L.P against Par Pharmaceutical Companies, Inc. relating to Ultram(R) ER, the reference product in Cipher's New Drug Application for CIP-TRAMADOL ER. This decision further mitigates any remaining risk of litigation on these patents against CIP-TRAMADOL ER.

      During Q3 2010, Cipher announced that the U.S. Patent and Trademark Office issued a Patent Notice of Allowance for CIP-TRAMADOL ER. Subsequent to quarter end, the Company also received Patent Notice of Allowance from the Canadian Intellectual Property Office. Both patents are expected to be issued this quarter. Cipher is currently preparing for the U.S. commercial launch of CIP-TRAMADOL ER, which includes securing a marketing partner and finalizing commercial manufacturing requirements. Cipher is targeting the first half of 2011 for commercial launch, at which point the product will provide a second royalty revenue stream to the Company.

      Cipher continues to actively pursue new early stage pipeline product candidates and advance out-licensing discussions for its current products.

          
          Conference Call and Webcast
          ---------------------------
          
      

      Cipher will hold a conference call today, October 27, 2010, at 8:30 a.m. (ET) to discuss its financial results and other corporate developments. To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191. A live audio webcast of the call will be available at www.cipherpharma.com. The webcast will be archived for 90 days.

      About Cipher Pharmaceuticals Inc.

      Cipher Pharmaceuticals is a commercial-stage drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher's products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company's lead compound is being marketed in the United States by Kowa Pharmaceuticals America under the label Lipofen(R). Cipher's second product, an extended-release version of the pain reliever tramadol, received FDA approval in May 2010 and the Company's third product, a novel formulation of the acne treatment isotretinoin, is in its final Phase III safety study.

      Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and has approximately 24 million shares outstanding. For more information, please visit www.cipherpharma.com.

      Forward-Looking Statements

      Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Company's Annual Information Form and other filings with Canadian securities regulatory authorities, such as the applicability of patents and proprietary technology; possible patent litigation; regulatory approval of products in the Company's pipeline; changes in government regulation or regulatory approval processes; government and third-party payer reimbursement; dependence on strategic partnerships for product candidates and technologies, marketing and R&D services; meeting projected drug development timelines and goals; intensifying competition; rapid technological change in the pharmaceutical industry; anticipated future losses; the ability to access capital to fund R&D; and the ability to attract and retain key personnel. All forward-looking statements presented herein should be considered in conjunction with such filings. Except as required by Canadian securities laws, the Company does not undertake to update any forward-looking statements; such statements speak only as of the date made.

          
      
                               Cipher Pharmaceuticals Inc.
      
                             Unaudited Financial Statements
      
                      For the Three Months Ended September 30, 2010
      
      
      
          Cipher Pharmaceuticals Inc.
          Unaudited Balance Sheets
          (in thousands of dollars)
      
                                                                    As at
                                                         September 30, December 31,
                                                                 2010         2009
      
          ASSETS
      
          Current assets
          Cash                                            $    10,538  $     9,006
          Accounts receivable                                   1,545          967
          Prepaid expenses and other current assets                93          457
          Loan receivable                                           -          800
          -------------------------------------------------------------------------
                                                               12,176       11,230
      
          Property and equipment, net                              62           86
      
          Intangible assets, net (note 3)                       3,683        3,507
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
                                                          $    15,921  $    14,823
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          LIABILITIES
      
          Current liabilities
          Accounts payable and accrued liabilities        $     2,566  $     1,570
          Current portion of deferred revenue                     928        1,956
          -------------------------------------------------------------------------
                                                                3,494        3,526
      
          Deferred revenue                                      1,131          329
          -------------------------------------------------------------------------
                                                                4,625        3,855
          -------------------------------------------------------------------------
      
          SHAREHOLDERS' EQUITY
      
          Share capital (note 4)                               49,977       49,948
          Contributed surplus                                  32,596       32,268
          Deficit                                             (71,277)     (71,248)
          -------------------------------------------------------------------------
                                                               11,296       10,968
          -------------------------------------------------------------------------
      
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
                                                          $    15,921  $    14,823
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          The accompanying notes are an integral part of these unaudited financial
          statements
      
      
      
          Cipher Pharmaceuticals Inc.
          Unaudited Statements of Operations and Comprehensive Loss
          (in thousands of dollars, except per share amounts)
      
      
                              For the three months ended  For the nine months ended
                                          September 30              September 30
                                       2010         2009         2010         2009
      
          Revenues
            Licensing revenue   $     1,081  $     1,067  $     4,217  $     2,347
          -------------------------------------------------------------------------
      
          Expenses
            Research and
             development                220          247          743          701
            Operating, general
             and administrative         955        1,157        2,975        3,203
            Amortization of
             property and
             equipment                   12           19           40           56
            Amortization of
             intangible assets          176          188          528          565
            Interest income             (22)         (26)         (40)         (99)
          -------------------------------------------------------------------------
      
                                      1,341        1,585        4,246        4,426
          -------------------------------------------------------------------------
      
      
          Loss and comprehensive
           loss for the period  $      (260)  $     (518)  $      (29) $    (2,079)
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          Basic and diluted
           loss per share
           (note 5)             $     (0.01)  $    (0.02)  $     0.00  $     (0.09)
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          The accompanying notes are an integral part of these unaudited financial
          statements
      
      
      
          Cipher Pharmaceuticals Inc.
          Unaudited Statements of Deficit
          (in thousands of dollars)
      
      
                              For the three months ended  For the nine months ended
                                          September 30              September 30
                                       2010         2009         2010         2009
      
          Deficit, beginning
           of period            $   (71,017) $   (70,094) $   (71,248) $   (68,533)
      
          Loss for the period          (260)        (518)         (29)      (2,079)
          -------------------------------------------------------------------------
          Deficit, end of
           period               $   (71,277) $   (70,612) $   (71,277) $   (70,612)
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          The accompanying notes are an integral part of these unaudited financial
          statements
      
      
      
          Cipher Pharmaceuticals Inc.
          Unaudited Statements of Cash Flows
          (in thousands of dollars)
      
      
                              For the three months ended  For the nine months ended
                                          September 30              September 30
                                       2010         2009         2010         2009
      
          Cash provided by
           (used in)
      
          Operating activities
            Loss                $      (260) $      (518) $       (29) $    (2,079)
            Items not affecting
             cash
              Amortization of
               property and
               equipment                 12           19           40           56
              Amortization of
               intangible assets        176          188          528          565
              Stock-based
               compensation
               expense                   93          165          342          490
              Imputed interest            -          (20)           -          (67)
          -------------------------------------------------------------------------
                                         21         (166)         881       (1,035)
            Net change in
             non-cash
             operating items            578         (123)         556           14
          -------------------------------------------------------------------------
      
                                        599         (289)       1,437       (1,021)
          -------------------------------------------------------------------------
      
          Investing activities
            Proceeds from loan
             receivable                   -            -          800          612
            Purchase of property
             and equipment               (2)          (3)         (16)          (8)
            Acquisition of
             intangible rights
             (note 3)                  (369)           -         (704)        (122)
          -------------------------------------------------------------------------
      
                                       (371)          (3)          80          482
          -------------------------------------------------------------------------
          Financing activities
            Proceeds from
             exercise of stock
             options                      -            -           15            -
          -------------------------------------------------------------------------
      
          Increase (Decrease)
           in cash                      228         (292)       1,532         (539)
          Cash, beginning of
           period                    10,310        9,634        9,006        9,881
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
          Cash, end of period   $    10,538  $     9,342  $    10,538  $     9,342
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          The accompanying notes are an integral part of these unaudited financial
          statements
      
      
      
          Cipher Pharmaceuticals Inc.
          Notes to Unaudited Financial Statements
          September 30, 2010
          (in thousands of dollars, except per share amounts)
      
      
          1   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
      
              Basis of presentation
              The accompanying unaudited interim financial statements of the
              Company have been prepared in accordance with accounting principles
              generally accepted in Canada for interim reporting. Accordingly,
              these financial statements do not include all of the disclosures
              required by generally accepted accounting principles for annual
              financial statements and should be read in conjunction with the
              annual financial statements of the Company. In the opinion of
              management, all adjustments considered necessary for fair
              presentation have been included. All such adjustments are of a normal
              recurring nature. Operating results for the nine months ended
              September 30, 2010 are not necessarily indicative of the results that
              may be expected for the fiscal year ending December 31, 2010.
      
              There have been no changes to the accounting policies as described in
              Note 1 to the financial statements for the year ended December 31,
              2009.
      
          2   LOAN RECEIVABLE
      
              During the quarter ended March 31, 2010, the Company received the
              final instalment of $800 as part of the deferred payment agreement
              from the sale of Pharma Medica Research Inc. in February 2005.
      
          3   INTANGIBLE ASSETS
      
              The Company has entered into certain agreements with Galephar
              Pharmaceutical Research Inc. ("Galephar") for the rights to package,
              test, obtain regulatory approvals and market certain products in
              various countries around the world. In accordance with the terms of
              the agreements, the Company has acquired these intangible rights
              through an investment in three separate series of preferred shares of
              Galephar. The preferred shares are redeemable by the Company from
              amounts received under licensing agreements for the products. The
              Company may be required to pay additional amounts to Galephar in
              respect of the CIP-ISOTRETINOIN and CIP-TRAMADOL ER intangible rights
              of up to $747 (US$725) if certain future milestones are achieved as
              defined in the agreements. These additional payments will be made in
              the form of additional Galephar preferred share purchases. The
              recovery of these intangible rights is dependant upon sufficient
              revenues being generated from the related products currently under
              development and commercialization. The Company is currently
              amortizing the intangible rights related to CIP-FENOFIBRATE and
              CIP-ISOTRETINOIN. After product-related expenses are deducted and
              after the recovery of Cipher's investment in the preferred shares of
              Galephar, approximately 50% of all milestone and royalties received
              by the Company under licensing agreements will be paid to Galephar.
      
              CIP-FENOFIBRATE - in July 2007 the Company entered into a licensing
              and distribution agreement with Kowa Pharmaceuticals America, Inc.
              ("Kowa"), under which Kowa was granted the exclusive right to market,
              sell and distribute Lipofen in the United States. Lipofen was
              launched in the U.S. market in 2007. During the second quarter of
              2010, the Company reached a cumulative net sales level for the
              product that resulted in a contract milestone of US$1 million being
              achieved.
      
              CIP-ISOTRETINOIN - in August 2008, the Company entered into a
              development, distribution and supply agreement with Ranbaxy
              Pharmaceuticals Inc. ("Ranbaxy") under which Ranbaxy was granted the
              exclusive right to market, sell and distribute the product in the
              United States. To date, the Company has received an up-front
              licensing payment of US$1 million and a milestone payment of
              US$2 million as a result of reaching 50% of the patient enrolment
              level for the clinical trial. Under the terms of the agreement the
              Company could receive additional pre- and post-commercialization
              milestone payments of up to US$21 million, based on the achievement
              of certain milestone targets. Once the product is commercialized, the
              Company will also receive a royalty based on a percentage of net
              sales. In addition, Ranbaxy will reimburse the Company for the costs
              associated with the clinical studies required by the FDA to secure
              NDA approval, up to a predetermined cap. Any additional development
              costs associated with initial FDA approval will be shared equally.
              The Company is responsible for all product development activities,
              including management of the clinical studies required by the FDA to
              secure NDA approval and is also responsible for product supply and
              manufacturing, which will be fulfilled by Galephar.
      
              CIP-TRAMADOL ER - In May 2010, the Company received final approval
              from the FDA for its extended-release tramadol product for the
              treatment of moderate to moderately severe chronic pain in adults.
              The achievement of FDA approval triggers additional milestone
              payments to Galephar as the Company prepares for commercial
              manufacturing. During the third quarter of 2010 payments of $369
              ($704 for the nine months ended September 30, 2010) were made to
              acquire additional intangible rights for CIP-TRAMADOL ER.
      
      
          4   SHARE CAPITAL
      
              Authorized share capital
      
              The authorized share capital consists of an unlimited number of
              preference shares, issuable in series, and an unlimited number of
              voting common shares.
      
              Issued share capital
      
              The following is a summary of the changes in share capital from
              December 31, 2008 to September 30, 2010:
      
                                                            Number of
                                                          common shares     Amount
                                                          (in thousands)       $
      
              Balance outstanding - December 31, 2008
               and December 31, 2009                             24,055     49,948
                 Options exercised during Q2 2010                    25         29
                                                         --------------------------
              Balance outstanding - September 30, 2010           24,080     49,977
                                                         --------------------------
                                                         --------------------------
      
              Stock option plan
      
              The following is a summary of the changes in the stock options
              outstanding from December 31, 2008 to September 30, 2010:
      
      
      
                                                                          Weighted
                                                                           average
                                                              Number of   exercise
                                                               options      price
                                                           (in thousands)     $
      
              Balance outstanding - December 31, 2008             1,376       2.51
                Granted in 2009                                     224       0.60
                Expired in 2009                                     (20)      4.33
                                                           --------------
              Balance outstanding - December 31, 2009             1,580       2.22
      
                Granted during the three months ended
                 March 31, 2010 (a)                                 222       1.60
                Exercised during the three months
                 ended June 30, 2010 (b)                            (25)      0.61
                                                           --------------
              Balance outstanding - September 30, 2010            1,777       2.17
                                                           --------------
                                                           --------------
      
              At September 30, 2010, 1,054,560 options were fully vested and
              exercisable (766,974 at September 30, 2009).
      
              (a) During the three months ended March 31, 2010, the Company issued
              221,500 stock options under the employee and director stock option
              plan, which have an exercise price of $1.60, 25% of which vest on
              February 19 of each year, commencing in 2011, and expire in 2020.
              Total compensation cost for these stock options is estimated to be
              $317. This cost will be recognized over the vesting period of the
              stock options.
      
              The stock options issued during the three months ended March 31, 2010
              were valued using the Black-Scholes option pricing model with the
              following assumptions:
      
                  Risk-free interest rate           3.50%
                  Expected life                  10 years
                  Expected volatility                 97%
                  Expected dividend                   Nil
      
              (b) During the three months ended June 30, 2010, 25,000 stock options
              were exercised for a total cash consideration of $15. Capital stock
              increased by $29 representing the cash consideration of $15 and a $14
              reduction in contributed surplus.
      
          5   LOSS PER SHARE
      
              Loss per share is calculated using the weighted average number of
              shares outstanding. The weighted average number of shares outstanding
              for the three and nine month periods ended September 30, 2010 was
              24,079,878 and 24,068,706 respectively (for both the three and nine
              month periods ended September 30, 2009 the amount was 24,054,878).
      
              As the Company had a loss for each of the periods presented, basic
              and diluted loss per share are the same because the exercise of all
              stock options would have an anti-dilutive effect.
          
      

      For further information: Craig Armitage, Investor Relations, The Equicom Group, (416) 815-0700 ext 278, (416) 815-0080 fax, [email protected]; Larry Andrews, President and CEO, Cipher Pharmaceuticals, (905) 602-5840 ext 324, (905) 602-0628 fax, [email protected]

      Modal title

      Organization Profile

      Cipher Pharmaceuticals Inc.

        Also from this source

      • Cipher Pharmaceuticals Reports Third Quarter 2026 Results

      • Cipher Pharmaceuticals Schedules Q3 2026 Earnings Release and Conference Call

      • Cipher Pharmaceuticals Announces the Appointment of Rajiv De Silva to its Board of Directors

      Contact PR Newswire

      • 866-245-2317
        from 7:30 AM - 6:30 PM ET
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • Investor Relations

      About

      • About PR Newswire
      • About Cision
      • Careers
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • Platform Login
      • Privacy Policy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      • Next Gen Communications Cloud
      • Cision Communications Cloud
      • my CNW
      877-269-7890
      from 8 AM - 10 PM ET
      • Terms of Use
      • Information Security Policy
      • Site Map
      • Cookie Settings
      • Accessibility Statement
      Copyright © 2026 CNW Group Ltd. All Rights Reserved. A Cision company.